GlaxoSmithKline PakistanKAR:GLAXO +1.66%92 Dividend Yield % is 4.59% as of Jul. 01, 2026, which is 13% above its 10-year median of 4.07. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 516 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 85.85% on this metric.
As of today (2026-07-01), the Trailing Annual Dividend Yield of GlaxoSmithKline Pakistan is 4.59%.
Good Sign:
GlaxoSmithKline Pakistan Ltd stock Dividend Yield % is close to 3-year high.
The historical rank and industry rank for GlaxoSmithKline Pakistan's Dividend Yield % or its related term are showing as below:
KAR:GLAXO'
s Dividend Yield % Range Over the Past 10 Years
Min: 1.51 Med: 4.07 Max: 9.69
Current: 4.59
During the past 13 years, the highest Dividend Yield of GlaxoSmithKline Pakistan was 9.69%. The lowest was 1.51%. And the median was 4.07%.
KAR:GLAXO's Dividend Yield % is ranked better than 85.85% of 516
companies
in the Drug Manufacturers industry
Industry Median: 1.965
vs KAR:GLAXO: 4.59
During the past 3 years, the average Dividends Per Share Growth Rate was 28.90% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of GlaxoSmithKline Pakistan was 37.00% per year. The lowest was -22.80% per year. And the median was 3.60% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
GlaxoSmithKline Pakistan Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
PKR 12.000000
2026-04-24
2026-04-24
2026-05-06
Cash Dividend
semi-annually
PKR:PKR 1.000000
PKR 5.000000
2025-09-05
2025-09-08
2025-09-19
Cash Dividend
semi-annually
PKR:PKR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Dividend Yield % of 4.59% as of Jul. 01, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 13% above median its historical median of 4.07. Over the past decade, GlaxoSmithKline Pakistan's Dividend Yield % has ranged from 1.51 to 9.69. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #73 out of 516 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is GlaxoSmithKline Pakistan's Dividend Yield % too high?
GlaxoSmithKline Pakistan's current Dividend Yield % of 4.59% is 13% above median its 10-year median of 4.07. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 9.69. The Drug Manufacturers industry median Dividend Yield % is 1.97. GlaxoSmithKline Pakistan's value of 4.59% is 133.6% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #73 out of 516 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #73 out of 516 companies for Dividend Yield %. This places GlaxoSmithKline Pakistan in the top 14% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 1.97. GlaxoSmithKline Pakistan's value of 4.59% is 133.6% above this benchmark. Historically, GlaxoSmithKline Pakistan's own Dividend Yield % has ranged from 1.51 to 9.69 over the past decade. While the company's 10-year median is 4.07 vs. the industry median of 1.97, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.97, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Dividend Yield % of 4.59% is 133.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Dividend Yield % is 4.59%, which is 13% above median its own 10-year median of 4.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Dividend Yield % is 4.59%, which is 13% above median its 10-year median of 4.07 and 133.6% above the Drug Manufacturers industry median of 1.97. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Dividend Yield % is 4.59% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Dividend Yield %: 4.59% (13% above median its 10-year median of 4.07)
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 133.6% above the Drug Manufacturers median (#73 of 516)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
